Patents by Inventor Edgardo Delfino Carosella
Edgardo Delfino Carosella has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11401318Abstract: Multimeric polypeptides and pharmaceutical uses thereof; multimers of alpha3 peptides of an HLA-G antigen and methods of producing such multimers, pharmaceutical compositions comprising the same, as well as their uses for treating various diseases including organ/tissue rejection. The multimers include at least two monomers, each of said monomers being selected in the group consisting of a peptide P1 of formula X1-X2, wherein X1 represents a peptidic linker including a cysteine amino acid and X2 represents an alpha3 domain of HLA-G.Type: GrantFiled: January 11, 2018Date of Patent: August 2, 2022Assignee: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVESInventors: Joel Le Maoult, Edgardo Delfino Carosella
-
Publication number: 20200158715Abstract: The present invention relates to methods for prognosis and monitoring of a cancer, preferably bladder cancer, by measuring the proportion of CD8+ T Lymphocytes expressing ILT-2 and the plasma level of soluble HLA-G. The invention also relates to anti HLA-G antibodies for use for treating a cancer in which tumor cells express HLA-G, preferably bladder cancer.Type: ApplicationFiled: January 28, 2020Publication date: May 21, 2020Inventors: François Desgrandchamps, Edgardo Delfino Carosella, Joël Lemaoult
-
Patent number: 10545136Abstract: The present invention relates to methods for prognosis and monitoring of a cancer, preferably bladder cancer, by measuring the proportion of CD8+ T Lymphocytes expressing ILT-2 and the plasma level of soluble HLA-G. The invention also relates to anti HLA-G antibodies for use for treating a cancer in which tumor cells express HLA-G, preferably bladder cancer.Type: GrantFiled: October 16, 2015Date of Patent: January 28, 2020Assignees: ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, Université Paris Diderot—Paris 7Inventors: François Desgrandchamps, Edgardo Delfino Carosella, Joël Lemaoult
-
Publication number: 20180194830Abstract: Multimeric polypeptides and pharmaceutical uses thereof; multimers of alpha3 peptides of an HLA-G antigen and methods of producing such multimers, pharmaceutical compositions comprising the same, as well as their uses for treating various diseases including organ/tissue rejection. The multimers include at least two monomers, each of said monomers being selected in the group consisting of a peptide P1 of formula X1-X2, wherein X1 represents a peptidic linker including a cysteine amino acid and X2 represents an alpha3 domain of HLA-G.Type: ApplicationFiled: January 11, 2018Publication date: July 12, 2018Applicant: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVESInventors: Joel LE MAOULT, Edgardo Delfino CAROSELLA
-
Publication number: 20170219561Abstract: The present invention relates to methods for prognosis and monitoring of a cancer, preferably bladder cancer, by measuring the proportion of CD8+ T Lymphocytes expressing ILT-2 and the plasma level of soluble HLA-G. The invention also relates to anti HLA-G antibodies for use for treating a cancer in which tumor cells express HLA-G, preferably bladder cancer.Type: ApplicationFiled: October 16, 2015Publication date: August 3, 2017Inventors: François Desgrandchamps, Edgardo Delfino Carosella, Joël Lemaoult
-
Patent number: 9359424Abstract: Multimeric polypeptides and pharmaceutical uses thereof; multimers comprising alpha3 and alpha1 peptides of an HLA-G antigen and methods of producing such multimers, pharmaceutical compositions comprising the same, as well as their uses for treating various diseases including organ/tissue rejection. Said multimers comprise at least two monomers, each of said monomers being selected in the group consisting of a peptide P2 of formula P1-X3 or X2-X3, wherein P1 is of formula X1-X2, wherein X1 represents a peptidic linker including a cysteine amino acid and X2 represents an alpha1 domain (or alpha1 peptide) of HLA-G and X3 represents an alpha3 domain of HLA-G.Type: GrantFiled: June 25, 2010Date of Patent: June 7, 2016Assignee: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVESInventors: Joel Le Maoult, Edgardo Delfino Carosella
-
Publication number: 20120178703Abstract: Multimeric polypeptides and pharmaceutical uses thereof; multimers comprising alpha3 peptides of an HLA-G antigen and methods of producing such multimers, pharmaceutical compositions comprising the same, as well as their uses for treating various diseases including organ/tissue rejection. Said multimers comprise at least two monomers, each of said monomers being selected in the group consisting of a peptide P1 of formula X1?X2, wherein X1 represents a peptidic linker including a cysteine amino acid and X2 represents an alpha3 domain (SEQ ID NO:1) of HLA-G.Type: ApplicationFiled: June 25, 2010Publication date: July 12, 2012Applicant: COMMISARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVESInventors: Joël Le Maoult, Edgardo Delfino Carosella
-
Publication number: 20120164164Abstract: Multimeric polypeptides and pharmaceutical uses thereof; multimers comprising alpha3 and alpha1 peptides of an HLA-G antigen and methods of producing such multimers, pharmaceutical compositions comprising the same, as well as their uses for treating various diseases including organ/tissue rejection. Said multimers comprise at least two monomers, each of said monomers being selected in the group consisting of a peptide P2 of formula P1-X3 or X2-X3, wherein P1 is of formula X1-X2, wherein X1 represents a peptidic linker including a cysteine amino acid and X2 represents an alpha1 domain (or alpha1 peptide) of HLA-G and X3 represents an alpha3 domain of HLA-G.Type: ApplicationFiled: June 25, 2010Publication date: June 28, 2012Applicant: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALTInventors: Joel Le Maoult, Edgardo Delfino Carosella
-
Publication number: 20110189238Abstract: The invention relates to a novel use of the soluble forms of HLA-G in the treatment or prophylaxis of abnormal B-cell proliferation, such as liquid cancers of the B type.Type: ApplicationFiled: July 31, 2009Publication date: August 4, 2011Applicant: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENE ALTInventors: Nathalie Rouas-Freiss, Edgardo Delfino Carosella
-
Publication number: 20040209296Abstract: The invention concerns a method for selecting tumours expressing HLA-G, sensitive to an anticancer treatment, which inhibits or prevents the HLA-G activity of said tumours and the uses thereof. Said method enable to establish either the HLA-G, transcription profile of a solid tumour or the HLA-G expression profile of a solid tumour. The method for establishing the HLA-G transcription profile consists in: (i) drawing a tumoral sample; (ii) extracting the mRNA; (iii) reverse transcription (RT) of said RNA: (iv) successive or simultaneous amplification of the cDNA's obtained in (iii) in the presence of primers specific to each HLA-G isoform and analysing the resulting amplification products, by electrophoresis and/or specific hybridisation and(v) establishing said sample HLA-G transcription profile.Type: ApplicationFiled: March 1, 2004Publication date: October 21, 2004Applicant: COMMISSARIAT A L'ENERGIE ATOMIQUEInventors: Edgardo Delfino Carosella, Jean Dausset, Philippe Moreau, Pascale Paul, Nathalie Rouas-Freiss
-
Patent number: 6790638Abstract: The invention concerns a method for selecting tumours expressing HLA-G, sensitive to an anticancer treatment, which inhibits or prevents the HLA-G activity of said tumours and the uses thereof. Said method enable to establish either the HLA-G, transcription profile of a solid tumour or the HLA-G expression profile of a solid tumour. The method for establishing the HLA-G transcription profile consists in: (i) drawing a tumoral sample; (ii) extracting the mRNA; (iii) reverse transcription (RT) of said RNA: (iv) successive or simultaneous amplification of the cDNA's obtained in (iii) in the presence of primers specific to each HLA-G isoform and analysing the resulting amplification products, by electrophoresis and/or specific hybridisation and (v) establishing said sample HLA-G transcription profile.Type: GrantFiled: October 13, 2000Date of Patent: September 14, 2004Assignee: Commissariat a l'Energie AtomiqueInventors: Edgardo Delfino Carosella, Jean Dausset, Philippe Moreau, Pascale Paul, Nathalie Rouas-Freiss
-
Patent number: 6528304Abstract: The invention concerns the use of a eukaryotic cell coding for at least an HLA-G isoform, to obtain an immunomodulating medicine for inhibiting the activity of killer cells, in particular NK cells and/or for inhibiting the primary allogenic response, in parthologies or situations in which the killer cells are activated or for preparing a medicine to raise the inhibiting function of the isoform(s) expressed by said cells with respect to killer cells, in particular NK cells, in pathologies where these killer cells are inhibited by the molecule of the major histocompatibility complex of I HLA-G classes. The invention also concerns eukaryotic cells expressing at their surface at least an HLA-G isoform and their applications. The invention further concerns transgenic animals specifically expressing at least an HLA-G isoform.Type: GrantFiled: October 21, 1998Date of Patent: March 4, 2003Assignee: Commissariat A l'Energie AtomiqueInventors: Edgardo Delfino Carosella, Jean Dausset, Marek Kirszenbaum, Pascale Paul, Nathalie Rouas-Freiss
-
Publication number: 20020052487Abstract: Transcripts of the major histocompatibility complex (MHC) Class I HLA-G gene which are present in foetal trophoblasts and/or in adult circulating mono-nuclear cells, as well as their applications.Type: ApplicationFiled: March 19, 2001Publication date: May 2, 2002Applicant: Commissariat a L' Energie AtomiqueInventors: Edgardo Delfino Carosella, Philippe Moreau, Elaine Gluckman, Marek Kirszenbaum
-
Patent number: 6291659Abstract: Transcripts of the major histocompatibility complex (MHC) Class I HLA-G gene which are present in foetal trophoblasts and/or in adult circulating mono-nuclear cells, as well as their applications. Either the said transcripts comprise, in succession in the 5′ to 3′ direction: a fragment encoding the signal peptide (exon 1), a fragment encoding the &agr;1 domain (exon 2), a fragment encoding the &agr;2 domain (exon 3), a fragment encoding the transmembrane TM domain (exon 5), a fragment encoding the cytoplasmic domain (exon 6) and the 3′ untranslated fragment (exon 8), which sequence is designated HLA-G4, or the said transcripts comprise intron 4.Type: GrantFiled: October 27, 1997Date of Patent: September 18, 2001Assignee: Commissariat a l'Energie AtomiqueInventors: Edgardo Delfino Carosella, Philippe Moreau, Eliane Gluckman, Marek Kirszenbaum
-
Patent number: 5856442Abstract: Transcripts of the major histocompatibility complex (MHC) Class I HLA-G gene which are present in foetal trophoblasts and/or in adult circulating mono-nuclear cells, as well as methods of using these. Either the said transcripts comprise, in succession in the 5' to 3' direction: a fragment encoding the signal peptide (exon 1), a fragment encoding the .alpha.1 domain (exon 2), a fragment encoding the .alpha.2 domain (exon 3), a fragment encoding the transmembrane TM domain (exon 5), a fragment encoding the cytoplasmic domain (exon 6) and the 3' untranslated fragment (exon 8), which sequence is designated HLA-G4, or the said transcripts comprise intron 4.Type: GrantFiled: March 17, 1995Date of Patent: January 5, 1999Assignee: Commissariat a l'Energie AtomiqueInventors: Edgardo Delfino Carosella, Philippe Moreau, Eliane Gluckman, Marek Kirszenbaum